A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population

The main objective of the study is to evaluate whether the extended duration fidaxomicin therapy is superior to the standard vancomycin therapy in sustained clinical cure of CDI at 30 days after end of treatment (Day 40 or Day 55).

本研究的主要目的为评估延长疗程的非达霉素（fidaxomicin）疗法相较于标准疗程万古霉素（vancomycin）疗法，在治疗结束后30天（对应第40天或第55天）实现艰难梭菌感染（CDI）的持续临床治愈效果是否更优。